The estimated Net Worth of Mohammad Hirmand is at least $8.68 Миллион dollars as of 9 February 2022. Mr. Hirmand owns over 669 units of Turning Point Therapeutics Inc stock worth over $519,756 and over the last 5 years he sold TPTX stock worth over $1,264,714. In addition, he makes $6,896,390 as Executive Vice President и Chief Medical Officer at Turning Point Therapeutics Inc.
Sign up
Mr. Hirmand TPTX stock SEC Form 4 insiders trading
Mohammad has made over 2 trades of the Turning Point Therapeutics Inc stock since 2021, according to the Form 4 filled with the SEC. Most recently he sold 669 units of TPTX stock worth $24,285 on 9 February 2022.
The largest trade he's ever made was selling 10,300 units of Turning Point Therapeutics Inc stock on 4 January 2021 worth over $1,240,429. On average, Mohammad trades about 2,194 units every 80 days since 2019. As of 9 February 2022 he still owns at least 6,838 units of Turning Point Therapeutics Inc stock.
You can see the complete history of Mr. Hirmand stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Mohammad Hirmand biography
Mohammad Hirmand serves as Executive Vice President, Chief Medical Officer of the Company. Previously Dr. Hirmand served as Chief Medical Officer of Peloton Therapeutics, Inc., a biopharmaceutical company, from May 2017 to November 2019. Prior to that, he served in various roles at Medivation, Inc., a biopharmaceutical company, from 2007 to March 2017, including as Chief Medical Officer at the time of the acquisition by Pfizer, Inc. in 2016. Prior to Dr. Hirmand’s tenure at Medivation, he served in clinical development roles of increasing responsibility at Nuvelo, Inc. (now ARCA Biopharma, Inc.), SuperGen, Inc. (now Astex Pharmaceuticals, Inc.), Tularik, Inc. and Theravance Biopharma, Inc. Dr. Hirmand received his M.D. from Harvard Medical School and his B.A. in Biological Sciences and Economics from Cornell University.
What is the salary of Mohammad Hirmand?
As the Executive Vice President и Chief Medical Officer of Turning Point Therapeutics Inc, the total compensation of Mohammad Hirmand at Turning Point Therapeutics Inc is $6,896,390. There are 1 executives at Turning Point Therapeutics Inc getting paid more, with Yi Larson having the highest compensation of $12,579,400.
How old is Mohammad Hirmand?
Mohammad Hirmand is 50, he's been the Executive Vice President и Chief Medical Officer of Turning Point Therapeutics Inc since 2019. There are 12 older and 7 younger executives at Turning Point Therapeutics Inc. The oldest executive at Turning Point Therapeutics Inc is Garry Nicholson, 65, who is the Independent Director.
Insiders trading at Turning Point Therapeutics Inc
Over the last 6 years, insiders at Turning Point Therapeutics Inc have traded over $45,947,838 worth of Turning Point Therapeutics Inc stock and bought 2,385,408 units worth $60,168,920 . The most active insiders traders include Plc Gsk, Patrick Machado и Advisors Llc Orbi Med Capit.... On average, Turning Point Therapeutics Inc executives and independent directors trade stock every 21 days with the average trade being worth of $4,727,594. The most recent stock trade was executed by Paolo Tombesi on 27 July 2022, trading 1,183 units of TPTX stock currently worth $88,654.
What does Turning Point Therapeutics Inc do?
Turning Point Therapeutics is a clinical-stage precision oncology company with a pipeline of internally discovered investigational drugs designed to address key limitations of existing cancer therapies. The company's lead drug candidate, repotrectinib, is a next-generation kinase inhibitor targeting the ROS1 and TRK oncogenic drivers of non-small cell lung cancer and advanced solid tumors. Repotrectinib, which is being studied in a registrational Phase 2 study in adults and a Phase 1/2 study in pediatric patients, has shown antitumor activity and durable responses among kinase inhibitor treatment-naïve and pre-treated patients. The company's pipeline of drug candidates also includes TPX-0022, targeting MET, CSF1R and SRC, which is being studied in a Phase 1 trial of patients with advanced or metastatic solid tumors harboring genetic alterations in MET; TPX-0046, targeting RET, which is being studied in a Phase 1/2 trial of patients with advanced or metastatic solid tumors harboring genetic alterations in RET; and TPX-0131, a next-generation ALK inhibitor currently pending IND submission. Turning Point's next-generation kinase inhibitors are designed to bind to their targets with greater precision and affinity than existing therapies, with a novel, compact structure that has demonstrated an ability to potentially overcome treatment resistance common with other kinase inhibitors. The company is driven to develop therapies that mark a turning point for patients in their cancer treatment.
What does Turning Point Therapeutics Inc's logo look like?
Complete history of Mr. Hirmand stock trades at Turning Point Therapeutics Inc
Turning Point Therapeutics Inc executives and stock owners
Turning Point Therapeutics Inc executives and other stock owners filed with the SEC include:
-
Yi Larson,
Chief Financial Officer, Executive Vice President -
Mohammad Hirmand,
Executive Vice President, Chief Medical Officer -
Annette North,
Executive Vice President, General Counsel, Secretary -
Dr. Athena Maria Countouriotis M.D.,
Pres, CEO & Director -
Andrew John Partridge,
Exec. VP & Chief Commercial Officer -
Carol Gallagher,
Independent Director -
Dr. Mohammad Hirmand,
Exec. VP & Chief Medical Officer -
Patrick Machado,
Independent Director -
Annette C. North Esq., LLB,
Exec. VP, Gen. Counsel & Company Sec. -
Dr. Siegfried Reich Ph.D.,
Exec. VP & Chief Scientific Officer -
Simeon George,
Independent Director -
Sheila Gujrathi,
Chairman of the Board -
Jacob Chacko,
Independent Director -
Jim Mazzola,
IR Contact Officer -
Garry Nicholson,
Independent Director -
Heather Adams,
Vice President of Human Resources -
Brian Baker,
Vice President - Finance and Administration -
Siegfried Reich,
Executive Vice President, Chief Scientific Officer -
Athena Countouriotis,
President, Chief Executive Officer, Director -
Dr. Jeffrey P. Whitten,
Sr. VP of Pre-Clinical Devel. -
Brian Sun J.D., M.S.,
Sr. VP, Gen. Counsel & Corp. Sec. -
Dr. Gavin Hirst Ph.D.,
Sr. VP of Chemistry & Interim Chief Scientific Officer -
Raymond J. Furey J.D.,
Sr. VP & Chief Compliance Officer -
Dr. Adam D. Levy M.B.A., Ph.D.,
Sr. VP of Investor Relations & Corp. Communications -
Ed Gemo,
Sr. VP & Chief Information Officer -
Kyri K. Van Hoose,
VP of Accounting & Interim Principal Accounting Officer -
Paolo Tombesi,
Exec. VP & CFO -
Jingrong Jean Cui,
Director -
Plc Gsk,
Director -
Hongbo Lu,
Director -
Advisors Llc Orbi Med Capit...,
-
Asset Management, Lp Chen B...,
-
Carl L Gordon,
Director -
Barbara W. Bodem,
Director -
Mark J Alles,
Director -
Paolo Tombesi,
EVP & Chief Financial Officer -
Brian Sun,
SVP & General Counsel -
Steve M Sabus,
SVP & Chief Commercial Officer